A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
Latest Information Update: 02 Feb 2026
At a glance
- Drugs Antineoplastics (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 28 Jan 2026 Status changed from not yet recruiting to recruiting.
- 15 Dec 2025 New trial record